reflection objectives: To develop and validate a patient-based issue measure to evaluate symptoms in patients with community-acquired pneumonia (CAP).

Design: A psychometric cogitation within an international, prospective, randomized, double-blind reflection The CAP-symptom questionnaire (CAP-Sym) is a fresh 18-item, patient-reported outcome measure that evaluates the bothersomeness of CAP-related symptoms during the past 24 h using a 6-point Likert scale. We used "gold standard" psychometric rules to comprehensively evaluate the acceptability, reliability, validity, and responsiveness of the CAP-Sym.

Setting: Sixty-four center in 13 countries (France, Germany, Hungary, Israel, Italy, Norway, Poland, Portugal, southward Africa, Spain, Sweden, Switzerland, United Kingdom).

Patients: Five hundr fifty-six patients with CAP, recruited from outpatient clinics, general practice, and hospital centers

Interventions: Randomization 1:1 to moxifloxacin (400 mg formerly daily), oral or standard oral treatment (amoxicillin, 1 g tid, or clarithromycin, 500 mg bid), alone or in combination, for up to 14 days.

Results: Standard psychometric trials confirmed the acceptability (item nonresponse, item-endorsement frequencies, item/scale floor and ceiling effects) reliability (internal consistency, item-total and inter-item correlations, test-retest reliability), validity (content originate convergent, discriminant, known groups), and responsiveness of the CAP-Sym.

Conclusions: The CAP-Sym is a practical and scientifically unhurt patient-based outcome measure of CAP-related symptoms that has been cause to growed using "gold standard" methods. As the simply fully validated measure of symptoms in patients with CAP, which is quick and easy to administer and is more responsive than the generic Medical consequences Study 36-Item Short-Form Health scan the CAP-Sym provides a practical and rigorous course for improving the evaluation of results in clinical trials and audit.

lock opener words: community-acquired pneumonia; outcomes; patient-based assessment; questionnaire; symptoms

Abbreviations: CAP = community-acquired pneumonia; CAP-Sym = community-acquired pneumonia symptom questionnaire; CAP-Sym 12 = 12-item community-acquired pneumonia symptom questionnaire; CAP-Sym 18 = 18-item community-acquired pneumonia symptom questionnaire; ICC = intraclass correlation coefficient; MC = SF-36 Mental constituent Summary score; PCS = SF-36 Physical constituent Summary; PSI = pneumonia severity index; SF-36 = Medical issues Study 36-Item Short-Form Health Survey

**********

Community-acquired pneumonia (CAP), defined as pneumonia not acquired in a hospital or long-term care institution, is a leading cause of morbidity and mortality worldwide. A fresh US study reported an annual CAP incidence of 56 million cases, with approximately 20% requiring hospitalization. (1) In the United Kingdom, approximately 50000 commonalty are admitted to hospital annually with CAP. (2) Among hospitalized patients, mortality ranges from 2 to 21% and rises to > 50% among patients with rigid disease, (3) making CAP the greatest in quantity common cause of death to be paid to infectious disease. (4)

newly introduced guidelines for the management of CAP (5-9) provide algorithms to guide clinical decision making about the choice of antimicrobials. As an alternative to aminopenicillins and/or macrolides, now passing guidelines also recommend a strange "respiratory" fluoroquinolone as a potential first-line option. In addition to their known efficacy, fluoroquinolones show the potential advantage of quicker symptom resolution and improved quality of life proper to their rapid bactericidal activity. It is therefore important that modern antimicrobial treatments in CAP be evaluated in succession the basis of rigorous assessment of patient-based issues such as symptoms and quality of life in addition to clinical outcomes

greatest in quantity studies evaluate treatment efficacy upon the basis of clinical results such as mortality, (10-12) bacteriologic rejoinder (10,13-15) temperature, (16) respiratory and heart rate, (17) clinical cure/response (1315) nature and severity of adverse events/safety, (10131517) and hospitalization. (10-1218) More newly come studies have also evaluated consequences on the basis of the health-care require to be paid [i]or[/i] undergones associated with outpatient visits, (19) inpatient hospitalizations, (1718) the use of antibiotics/antimicrobials, (1011) and time to respond to work or usual activities. (10)

Despite clear recognition that patient-based issues are a key component in evaluating health issues (20-22) only three studies have evaluated treatment efficacy in CAP using rigorous, validated measures of quality of life, (101719) and none have assessed symptoms using scientifically robust measures. pair studies (10,13) that have evaluated symptoms used unvalidated, clinician-reported ratings of patients' symptoms, and couple other studies (16,19) assessed patient-reported symptoms using scales that have not been completely evaluated for reliability, validity, and responsiveness. Our extensive review of the literature and skilled hand opinion from pneumologists, clinical researchers, and consequence researchers pointed to the ne for a practical and scientifically rigorous patient-based result measure to evaluate symptoms in CAP in clinical trials and audit.

...